Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML? Available to Purchase

2.

Récher

C

,

Röllig

C

,

Bérard

E

, et al.

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

.

Leukemia

.

2022

;

36

(

4

):

913

-

922

.

3.

Talati

C

,

Dhulipala

VC

,

Extermann

MT

, et al.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

.

Haematologica

.

2020

;

105

(

2

):

398

-

406

.

4.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

5.

Wei

AH

,

Loo

S

,

Daver

N.

How I treat patients with AML using azacitidine and venetoclax

.

Blood

.

2025

;

145

(

12

):

1237

-

1250

.

6.

Karrar

O

,

Abdelmagid

M

,

Rana

M

, et al.

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival

.

Am J Hematol

.

2024

;

99

(

2

):

E63

-

E66

.

7.

Willekens

C

,

Bazinet

A

,

Chraibi

S

, et al.

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

.

Blood Cancer J

.

2025

;

15

(

1

):

68

.

8.

Döhner

H

,

Pratz

KW

,

DiNardo

CD

, et al.

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

.

Blood

.

2024

;

144

(

21

):

2211

-

2222

.

9.

Konopleva

M

,

Popovic

R

,

Murray

L

, et al.

Genetic Insights Into Acquired Resistance and Clonal Evolution in Venetoclax (Ven)-Based Therapy for Acute Myeloid Leukemia (AML)

.

EHA

;

2024

:

S145

.

10.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

11.

Shu

W

,

Yang

Q

,

He

D

, et al.

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

.

Eur J Med Res

.

2025

;

30

(

1

):

354

.

12.

Zhang

Q

,

Riley-Gillis

B

,

Han

L

, et al.

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

.

Signal Transduct Target Ther

.

2022

;

7

(

1

):

51

.

13.

Pei

S

,

Pollyea

DA

,

Gustafson

A

, et al.

Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia

.

Cancer Discov

.

2020

;

10

(

4

):

536

-

551

.

14.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

15.

Moujalled

DM

,

Brown

FC

,

Chua

CC

, et al.

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

.

Blood

.

2023

;

141

(

6

):

634

-

644

.

16.

Sharon

D

,

Jung

P

,

Sun

Y

, et al.

DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance

.

Hemasphere

.

2023

;

7

(

suppl

):e7041879.

17.

Roca-Portoles

A

,

Rodriguez-Blanco

G

,

Sumpton

D

, et al.

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition

.

Cell Death Dis

.

2020

;

11

(

8

):

616

.

18.

Stevens

BM

,

Jones

CL

,

Pollyea

DA

, et al.

Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells

.

Nature Cancer

.

2020

;

1

(

12

):

1176

-

1187

.

19.

Moujalled

DM

,

Pomilio

G

,

Ghiurau

C

, et al.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

.

Leukemia

.

2019

;

33

(

4

):

905

-

917

.

20.

Diepstraten

ST

,

Yuan

Y

,

La Marca

JE

, et al.

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers

.

Cancer Cell

.

2024

;

42

(

5

):

850

-

868

.e9868e9.

21.

McMahon

CM

,

Ferng

T

,

Canaani

J

, et al.

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia

.

Cancer Discov

.

2019

;

9

(

8

):

1050

-

1063

.

22.

Kennedy

VE

,

Peretz

CA

,

Walia

A

, et al.

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance

.

bioRxiv

.

2025

. doi:10.1101/2025.02.02.636108.

23.

Chua

CC

,

Anstee

N

,

Flensburg

C

, et al.

Venetoclax has potent efficacy in NPM1 mutated AML with acquired resistance associated with either perturbed pro-survival signalling or NPM1 wild-type populations

.

Blood

.

2023

;

142

:

423

.

24.

Short

NJ

,

Loghavi

S

,

Yilmaz

M

, et al.

Long-term survival outcomes and cytogenetic/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor

.

Blood

.

2024

;

144

:

220

.

25.

Schmalbrock

LK

,

Dolnik

A

,

Cocciardi

S

, et al.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

.

Blood

.

2021

;

137

(

22

):

3093

-

3104

.

26.

Chua

CC

,

Hsu

B

,

Enjeti

AK

, et al.

A phase II randomized trial comparing low-dose cytarabine and venetoclax+/-midostaurin in non-adverse cytogenetic risk acute myeloid leukemia: the ALLG AMLM25 intervene trial

.

Blood

.

2024

;

144

:

217

.

27.

Ikoma

Y

,

Nakamura

N

,

Kaneda

Y

, et al.

Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML

.

Leukemia

.

2025

;

39

(

6

):

1362

-

1367

.

28.

Jongen-Lavrencic

M

,

Grob

T

,

Hanekamp

D

, et al.

Molecular minimal residual disease in acute myeloid leukemia

.

N Engl J Med

.

2018

;

378

(

13

):

1189

-

1199

.

29.

DiNardo

CD

,

Marvin-Peek

J

,

Loghavi

S

, et al.

Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy–ineligible patients with isocitrate dehydrogenase–mutated AML

.

J Clin Oncol

.

2025

;

43

(

24

):

2692

-

2699

.

30.

Singh Mali

R

,

Zhang

Q

,

DeFilippis

RA

, et al.

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

.

Haematologica

.

2021

;

106

(

4

):

1034

-

1046

.

31.

Altman

JK

,

Sun

Z

,

Perl

AE

, et al.

A randomized phase II study of venetoclax and HMA-based therapies for the treatment of older and unfit adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML): a myelomatch treatment trial: ECOG-ACRIN MM20A-EA02

.

Blood

.

2024

;

144

(

suppl 1

):2907.2901.

32.

De Gregori

S

,

Gelli

E

,

Capone

M

, et al.

Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia

.

Pharmaceutics

.

2023

;

15

(

6

):

1680

.

33.

Rausch

CR

,

DiNardo

CD

,

Maiti

A

, et al.

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

.

Cancer

.

2021

;

127

(

14

):

2489

-

2499

.

34.

Kawedia

JD

,

Rausch

CR

,

Liu

X

, et al.

Prospective pharmacokinetic evaluation of venetoclax in AML supports re-evaluation of recommended dose adjustments with azole antifungals

.

Am J Hematol

.

2025

;

100

(

4

):

740

-

743

.

35.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

36.

Wei

AH

,

Montesinos

P

,

Ivanov

V

, et al.

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

.

Blood

.

2020

;

135

(

24

):

2137

-

2145

.

37.

Bhatnagar

S

,

Mukherjee

D

,

Salem

AH

,

Miles

D

,

Menon

RM

,

Gibbs

JP

.

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach

.

Cancer Chemother Pharmacol

.

2021

;

87

(

4

):

465

-

474

.

38.

DiNardo

CD

,

Pratz

KW

,

Letai

A

, et al.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

.

Lancet Oncol

.

2018

;

19

(

2

):

216

-

228

.

39.

Sallman

DA

,

Al Malki

MM

,

Asch

AS

, et al.

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

.

J Clin Oncol

.

2023

;

41

(

15

):

2815

-

2826

.

40.

Greenberg

PL

,

Tuechler

H

,

Schanz

J

, et al.

Revised international prognostic scoring system for myelodysplastic syndromes

.

Blood

.

2012

;

120

(

12

):

2454

-

2465

.

41.

Zeidner

JF

,

Sallman

DA

,

Récher

C

, et al.

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

.

Blood

.

2025

;

146

(

5

):

590

-

600

.

42.

Bernard

E

,

Nannya

Y

,

Hasserjian

RP

, et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

.

Nat Med

.

2020

;

26

(

10

):

1549

-

1556

.

43.

Daver

N

,

Vyas

P

,

Huls

G

, et al.

ENHANCE-3: venetoclax and azacitidine plus magrolimab or placebo in untreated AML unfit for intensive therapy

.

Blood

.

2025

;

146

(

5

):

601

-

611

.

44.

Burnett

AK

,

Hills

RK

,

Hunter

AE

, et al; UK National Cancer Research Institute AML Working Group.

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

.

Leukemia

.

2013

;

27

(

1

):

75

-

81

.

45.

Burnett

AK

,

Russell

NH

,

Hunter

AE

, et al; UK National Cancer Research Institute AML Working Group.

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

.

Blood

.

2013

;

122

(

8

):

1384

-

1394

.

46.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

47.

Wei

AH

,

Panayiotidis

P

,

Montesinos

P

, et al.

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

.

Blood

.

2022

;

140

(

25

):

2754

-

2756

.

48.

Metzeler

KH

,

Herold

T

,

Rothenberg-Thurley

M

, et al; AMLCG Study Group.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

.

Blood

.

2016

;

128

(

5

):

686

-

698

.

49.

Döhner

H

,

Dolnik

A

,

Tang

L

, et al.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

.

Leukemia

.

2018

;

32

(

12

):

2546

-

2557

.

50.

Zeidan

A

,

Kovacsovics

T

,

Adriano

V

, et al.

PS1483: Primary results STIMULUS-AML1: a large, international, phase II study of sabatolimab combined with azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia (AML) patients (pts)

.

HemaSphere

.

2025

;

9

(

suppl 1

):

2433

-

2435

.

51.

Norsworthy

KJ

,

Gao

X

,

Ko

C-W

, et al.

Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses

.

J Clin Oncol

.

2022

:

40

(

8

):

847

-

854

.

52.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine

.

J Clin Oncol

.

2022

;

40

(

8

):

855

-

865

.

53.

Othman

J

,

Tiong

IS

,

O'Nions

J

, et al.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

.

Blood

.

2024

;

143

(

4

):

336

-

341

.

54.

Brown

FC

,

Wang

X

,

Birkinshaw

R

, et al.

Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia

.

Blood Adv

.

2025

;

9

(

1

):

127

-

131

.

55.

Katagiri

S

,

Chi

S

,

Minami

Y

, et al.

Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia

.

Int J Mol Sci

.

2022

;

23

(

9

):

4694

.

56.

Sango

J

,

Carcamo

S

,

Sirenko

M

, et al.

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

.

Nature

.

2024

;

636

(

8041

):

241

-

250

.

57.

Maity

R

,

Neri

P

,

Donovan

J

, et al.

Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients

.

Clin Lymphoma Myeloma Leuk

.

2019

;

19

(

suppl 10

):

e22

-

e23

.

58.

Kuusanmäki

H

,

Dufva

O

,

Vähä-Koskela

M

, et al.

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

.

Blood

.

2023

;

141

(

13

):

1610

-

1625

.

59.

Esteve-Arenys

A

,

Roue

G.

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma

.

Oncoscience

.

2018

;

5

(

3-4

):

59

-

61

.

60.

Carter

BZ

,

Mak

PY

,

Tao

W

, et al.

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition

.

Haematologica

.

2022

;

107

(

1

):

58

-

76

.

61.

Chen

X

,

Glytsou

C

,

Zhou

H

, et al.

Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment

.

Cancer Discov

.

2019

;

9

(

7

):

890

-

909

.

62.

Thijssen

R

,

Diepstraten

ST

,

Moujalled

D

, et al.

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

.

Blood

.

2021

;

137

(

20

):

2721

-

2735

.

63.

Pereira-Martins

D

,

Ortiz Rojas

CA

,

Weinhaeuser

I

, et al.

CEBPA-driven expression of the transcriptionally inactive deltaTP73 isoform phenocopies TP53mutated poor risk and drug-resistant acute myeloid leukemia

.

Blood

.

2023

;

142

(

suppl 1

):

839

.

64.

Roboz

GJ

,

Pabst

T

,

Aribi

A

, et al.

Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; an open-label, multicenter, phase 1b study

.

Blood

.

2021

;

138

:

369

.

65.

Buecklein

V

,

Magno

G

,

Rausch

C

, et al.

Abstract CT225: AARON: an ongoing open-label phase I/II study of relatlimab (anti-LAG-3) with nivolumab (anti-PD-1) in combination with azacitidine ± venetoclax for the treatment of patients with relapsed/refractory and non-fit patients with newly diagnosed acute myeloid leukemia—interim analysis

.

Cancer Res

.

2025

;

85

(

8

, suppl 2):

CT225

.

66.

Daver

N

,

Montesinos

P

,

Altman

JK

, et al.

Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia

.

Blood

.

2023

;

142

(

suppl 1

):

2906

.

67.

Borate

U

,

McMahon

C

,

Fenaux

P

, et al.

SELECT-AML-1: phase 2 randomized trial of tamibarotene in combination with venetoclax and azacitidine in adult patients with previously untreated AML with RARA overexpression, who are ineligible for standard induction therapy

.

Paper presented at: Society of Hematologic Oncology 12th Annual Meeting

;

Houston, TX

;

4 September 2024

.